In a congenic AML mouse model based on co-expression of an FLT3-ITD allele (which alone is insufficient to cause AML) with a Nup98-Hoxd13 fusion gene, in vivo treatment with atRA delayed disease onset, and enhanced corresponding effects of sorafenib, in secondary recipients. This evidence concerns the gene FLT3 and acute myeloid leukemia.